Optic Neuritis Clinical Trial
Official title:
Predictive Effect of Ganglion Cell Layer on Visual Acuity at 6 Months and on Visual Function at 1 Year After an Episode of Optic Neuritis
NCT number | NCT02864134 |
Other study ID # | 2017-2916 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2016 |
Est. completion date | February 28, 2019 |
Verified date | July 2019 |
Source | CHU de Quebec-Universite Laval |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
BACKGROUND AND OBJECTIVES: The recent expansion of the applications of optical coherence tomography (OCT) demonstrated a higher correlation between the analysis of ganglion cells and visual function, in comparison with the analysis of the nerve fiber layer for several diseases of the optic nerve. Atrophy of the ganglion cells tends to induce the visual function deficits. In the case of optic neuritis, inflammation of the optic nerve causes a deficit of visual function initially with low vision, color blindness and visual field. Secondary atrophy of ganglion cell can result. The purpose of the study is to evaluate the correlation between the analysis of ganglion cells at the time of diagnosis of optic neuritis and the resulting visual acuity at 6 months and visual function (visual acuity, color vision and perimetry) 1 year regardless of treatment. A predictive effect could help predict the patient's clinical course and management of uncertainty and anxiety. MATERIALS AND METHODS: An assessment at diagnosis and follow-ups at 6 months and 1 year with a measurement of best corrected visual acuity, a test color vision HRR (Hardy-Rand-Rittler), an OCT with analysis of ganglion cells and perimetry Humphrey 30 -2 fast will be done. Simple linear and logistic regressions will be used. RESULTS: We expect that there will be a significant association between atrophy of ganglion cells in the diagnosis and residual visual function after an episode of optic neuritis. We believe that the initial atrophy is associated with poorer visual prognosis. CONCLUSION: A predictive effect could help to inform the patient about the evolution of the disease and provide early visual rehabilitation.
Status | Completed |
Enrollment | 25 |
Est. completion date | February 28, 2019 |
Est. primary completion date | February 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Major and apt patients seen in consultation with diagnosis of optic neuritis Exclusion Criteria: - Concomitant ophthalmic diseases - known macular pathology - Amblyopia - Glaucoma - History of an ophthalmic surgery - Family history of hereditary optic neuropathy - Pathological myopia (refractive error of 8 diopters or more). - Known neurological disease other than multiple sclerosis. - Habit - Nutritional deficiency anorexia, restrictive gastrointestinal surgery. - Active or former professional or recreational exposure - Exposure to metals: lead, mercury, thallium - Exposure to solvents: ethylene glycol, toluene, styrene, perchlorethylene; - Prior poisoning: methanol, carbon dioxide. - Usual or earlier Medication - Taking one or more drugs known to cause toxic optic neuropathy* - listed available on demand |
Country | Name | City | State |
---|---|---|---|
Canada | Hopital Saint-Sacrement | Quebec |
Lead Sponsor | Collaborator |
---|---|
CHU de Quebec-Universite Laval |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association between the analysis of ganglion cells at diagnosis and the resulting visual acuity at 6 months after optic neuritis | Evaluation of best corrected visual acuity at 6 months post optic neuritis episode in correlation with initial ganglion cell layer analysis measures in order to predict the visual acuity in the future. | 6 months post optic neuritis | |
Primary | Association between the analysis of ganglion cells at diagnosis and the visual function at 12 months after optic neuritis | Evaluation of the visual function (best corrected visual acuity, perimetry, color vision) at 12 months post optic neuritis episode in correlation with initial ganglion cell layer analysis measures in order to predict the visual acuity in the future. | 12 months post optic neuritis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT00261326 -
Simvastatin Treatment of Patients With Acute Optic Neuritis
|
Phase 3 | |
Active, not recruiting |
NCT03963310 -
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
|
||
Recruiting |
NCT03586557 -
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
|
N/A | |
Recruiting |
NCT05487989 -
VIsual Pathways Model in Neuro-inflammatory Disorders
|
||
Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|
||
Not yet recruiting |
NCT06453694 -
Efgartigimod for the Treatment of Acute Optic Neuritis
|
Phase 2 | |
Completed |
NCT01962571 -
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
|
Phase 3 | |
Recruiting |
NCT03302585 -
High-Dose Vitamin D Induction in Optic Neuritis
|
Phase 2 | |
Recruiting |
NCT02886377 -
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
|
N/A | |
Completed |
NCT01987167 -
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
|
Early Phase 1 | |
Completed |
NCT01451593 -
Neuroprotection With Phenytoin in Optic Neuritis
|
Phase 2 | |
Completed |
NCT03630497 -
BN201 SAD MAD Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01337986 -
Ampyra for Optic Neuritis in Multiple Sclerosis
|
Phase 2/Phase 3 | |
Completed |
NCT01274702 -
Visual Reconstitution Therapy After Optic Neuritis
|
Phase 2 | |
Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
Withdrawn |
NCT00037115 -
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
|
Phase 4 | |
Not yet recruiting |
NCT06389968 -
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04257734 -
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT02939937 -
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
|
Phase 2 |